{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:37:30Z","timestamp":1763707050532,"version":"3.41.2"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010133","name":"Aarne Koskelo Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010133","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Finnish Foundation for Cardiovascular Research"},{"DOI":"10.13039\/100010114","name":"Yrj\u00f6 Jahnsson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Juselius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pulsus Foundation"},{"name":"Helsinki and Uusimaa Hospital District research fund","award":["TYH2019309","TYH2023319"],"award-info":[{"award-number":["TYH2019309","TYH2023319"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Direct oral anticoagulants (DOACs) at reduced dosage regimens are the first choice of ischaemic stroke (IS) prevention for patients with atrial fibrillation (AF) and elevated bleeding risk or renal insufficiency. We compared the outcomes of reduced dose DOACs and warfarin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We included all new-onset patients with AF in Finland from 2011 to 2018. Adjusted hazard ratios (HRs) for IS, intracranial haemorrhage (ICH), bleeding, and mortality were calculated for dabigatran (n = 2 672), rivaroxaban (n = 1 866), apixaban (n = 3 936), and warfarin (n = 43 548). Patients on warfarin were grouped into quartiles by their individual time-in-therapeutic range (TTR), with the second best TTR quartile as a reference group for comparisons. Risk of IS was highest in the low TTR quartiles of warfarin, lowest in the best TTR quartile (0.65 95% confidence interval, 0.51\u20130.83), and did not differ for dabigatran, rivaroxaban, and apixaban compared with the second best TTR quartile. Risk of ICH was highest in low TTR quartiles of warfarin (HRs 7.20, 5.48\u20139.46 and 1.91, 1.44\u20132.55), and was not different in patients on dabigatran, rivaroxaban, and apixaban. Risk of all-cause death and bleeding were lowest in the two best TTR quartiles, and highest in the poorest TTR group. Mortality was higher for dabigatran, rivaroxaban, and apixaban, compared with the second best TTR quartile of warfarin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DOACs with reduced doses are efficient and safe stroke prevention therapy in high-risk patients with AF when compared with warfarin therapy of sufficient TTR. In this comparison, warfarin therapy of excellent TTR-quality was associated with the lowest risk of bleeding and mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeaf046","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:19:11Z","timestamp":1745389151000},"source":"Crossref","is-referenced-by-count":1,"title":["Reduced dose direct oral anticoagulants and time-in-therapeutic-range defined warfarin in new-onset atrial fibrillation: a report from the nationwide FinACAF study"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-2781","authenticated-orcid":false,"given":"Alex","family":"Luojus","sequence":"first","affiliation":[{"name":"Heart and Lung Center, Helsinki University Hospital and University of Helsinki , Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-5142","authenticated-orcid":false,"given":"Mika","family":"Lehto","sequence":"additional","affiliation":[{"name":"Heart and Lung Center, Helsinki University Hospital and University of Helsinki , Helsinki, Finland"},{"name":"Department of Internal Medicine, Jorvi Hospital, Helsinki and Uusimaa Hospital District , Espoo ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-8435","authenticated-orcid":false,"given":"Olli","family":"Halminen","sequence":"additional","affiliation":[{"name":"Aalto University , Espoo ,","place":["Finland"]},{"name":"University of Eastern Finland , Kuopio ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4914-1027","authenticated-orcid":false,"given":"Ossi","family":"Lehtonen","sequence":"additional","affiliation":[{"name":"University of Eastern Finland , Kuopio ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-2189","authenticated-orcid":false,"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Individualized Drug Therapy Research Program, University of Helsinki , Helsinki ,","place":["Finland"]},{"name":"Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital , Helsinki ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-0994","authenticated-orcid":false,"given":"Konsta","family":"Teppo","sequence":"additional","affiliation":[{"name":"Turku University Hospital and University of Turku ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0569-058X","authenticated-orcid":false,"given":"Jaana","family":"Kuoppala","sequence":"additional","affiliation":[{"name":"University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1450-6208","authenticated-orcid":false,"given":"Jari","family":"Haukka","sequence":"additional","affiliation":[{"name":"University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-6104","authenticated-orcid":false,"given":"Jukka","family":"Putaala","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital and University of Helsinki , Helsinki ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-2484","authenticated-orcid":false,"given":"Miika","family":"Linna","sequence":"additional","affiliation":[{"name":"Aalto University , Espoo ,","place":["Finland"]},{"name":"University of Eastern Finland , Kuopio ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1319-0248","authenticated-orcid":false,"given":"Pirjo","family":"Mustonen","sequence":"additional","affiliation":[{"name":"Turku University Hospital and University of Turku ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-6740","authenticated-orcid":false,"given":"Aapo","family":"Aro","sequence":"additional","affiliation":[{"name":"Heart and Lung Center, Helsinki University Hospital and University of Helsinki , Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-107X","authenticated-orcid":false,"given":"Juha","family":"Hartikainen","sequence":"additional","affiliation":[{"name":"Kuopio University Hospital and University of Eastern \u00a0","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Yoke Hong","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Liverpool ,","place":["UK"]},{"name":"Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University , Aalborg ,","place":["Denmark"]},{"name":"Medical University of Bialystok , Bialystok ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0193-568X","authenticated-orcid":false,"given":"Kari Eino Juhani","family":"Airaksinen","sequence":"additional","affiliation":[{"name":"Turku University Hospital and University of Turku ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025062608245886400_oeaf046-B1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"key":"2025062608245886400_oeaf046-B2","doi-asserted-by":"crossref","first-page":"e002140","DOI":"10.1136\/openhrt-2022-002140","article-title":"Comprehensive nationwide incidence and prevalence trends of atrial fibrillation in Finland","volume":"9","author":"Lehto","year":"2022","journal-title":"Open Heart"},{"key":"2025062608245886400_oeaf046-B3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2025062608245886400_oeaf046-B4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2025062608245886400_oeaf046-B5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2025062608245886400_oeaf046-B6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2025062608245886400_oeaf046-B7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2025062608245886400_oeaf046-B8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2025062608245886400_oeaf046-B9","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"2025062608245886400_oeaf046-B10","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"2025062608245886400_oeaf046-B11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013vitamin K oral anticoagulants with and without concurrent medications and risk of Major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"2025062608245886400_oeaf046-B12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.thromres.2014.05.034","article-title":"The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI2 experience","volume":"134","author":"Barnes","year":"2014","journal-title":"Thromb Res"},{"key":"2025062608245886400_oeaf046-B13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025062608245886400_oeaf046-B14","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025062608245886400_oeaf046-B15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/heartjnl-2020-318753","article-title":"Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation","volume":"108","author":"Rutherford","year":"2022","journal-title":"Heart"},{"key":"2025062608245886400_oeaf046-B16","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/eurheartj\/ehy802","article-title":"Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"40","author":"Wang","year":"2019","journal-title":"Eur Heart J"},{"key":"2025062608245886400_oeaf046-B17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.06.004","article-title":"Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: a meta-analysis of randomized trials","volume":"244","author":"Carmo","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025062608245886400_oeaf046-B18","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"2025062608245886400_oeaf046-B19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10654-021-00812-x","article-title":"The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF): study rationale, design, and patient characteristics","volume":"37","author":"Lehto","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"2025062608245886400_oeaf046-B20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"2025062608245886400_oeaf046-B21","doi-asserted-by":"crossref","first-page":"2364825","DOI":"10.1080\/07853890.2024.2364825","article-title":"Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a nationwide cohort study","volume":"56","author":"Lehto","year":"2024","journal-title":"Ann Med"},{"key":"2025062608245886400_oeaf046-B22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2025062608245886400_oeaf046-B23","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"2025062608245886400_oeaf046-B24","doi-asserted-by":"crossref","first-page":"100967","DOI":"10.1016\/j.lanepe.2024.100967","article-title":"Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in atrial fibrillation (FinACAF) cohort","volume":"43","author":"Teppo","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025062608245886400_oeaf046-B25","doi-asserted-by":"crossref","first-page":"j510","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"Nielsen","year":"2017","journal-title":"BMJ"},{"key":"2025062608245886400_oeaf046-B26","doi-asserted-by":"crossref","first-page":"812018","DOI":"10.3389\/fphar.2021.812018","article-title":"Comparative effectiveness and safety of low-dose oral anticoagulants in patients with atrial fibrillation","volume":"12","author":"Perreault","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025062608245886400_oeaf046-B27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11239-022-02763-w","article-title":"Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation","volume":"55","author":"Jansson","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2025062608245886400_oeaf046-B28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ehjcvp\/pvz086","article-title":"Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study","volume":"6","author":"Rutherford","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025062608245886400_oeaf046-B29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1160\/th14-04-0346","article-title":"Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials","volume":"112","author":"Vanassche","year":"2014","journal-title":"Thromb Haemost"},{"key":"2025062608245886400_oeaf046-B30","doi-asserted-by":"crossref","first-page":"e002197","DOI":"10.1136\/openhrt-2022-002197","article-title":"Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"10","author":"Joosten","year":"2023","journal-title":"Open Heart"},{"key":"2025062608245886400_oeaf046-B31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","article-title":"Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"109","author":"Caso","year":"2023","journal-title":"Heart"},{"key":"2025062608245886400_oeaf046-B32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/eurheartj\/ehz014","article-title":"On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?","volume":"40","author":"Atar","year":"2019","journal-title":"Eur Heart J"},{"key":"2025062608245886400_oeaf046-B33","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025062608245886400_oeaf046-B34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/pds.4194","article-title":"Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF registry: quality of warfarin therapy","volume":"26","author":"Lehto","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025062608245886400_oeaf046-B35","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.19102\/icrm.2017.080302","article-title":"Time in the therapeutic range (TTR): an overly simplified conundrum","volume":"8","author":"Reiffel","year":"2017","journal-title":"J Innov Card Rhythm Manag"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeaf046\/62989512\/oeaf046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/3\/oeaf046\/62989512\/oeaf046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/5\/3\/oeaf046\/62989512\/oeaf046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:25:06Z","timestamp":1750940706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeaf046\/8118063"}},"subtitle":[],"editor":[{"given":"Frieder","family":"Braunschweig","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeaf046","relation":{},"ISSN":["2752-4191"],"issn-type":[{"type":"electronic","value":"2752-4191"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,23]]},"article-number":"oeaf046"}}